Receipt of FDA Concurrence

24 November 2015

Motif Bio plc

("Motif" or the "Company")

Receipt of FDA Concurrence with Optimized Dose for Iclaprim Phase III Clinical Trials

Motif Bio plc (AIM:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that it has received written concurrence from the United States Food and Drug Administration ("FDA") for an optimized fixed dose of iclaprim of 80mg for all patients except those with moderate hepatic impairment, regardless of bodyweight, in the Company's proposed Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections ("ABSSSI"). The fixed dose of iclaprim, together with the selected infusion time, optimizes pharmacodynamic parameters associated with antibacterial efficacy, while potentially minimizing safety events.

Iclaprim, a targeted spectrum antibiotic designed to be effective against multi-drug-resistant bacteria, including MRSA, will be tested in randomised, double blind, multicentre clinical trials to evaluate the efficacy and safety of intravenous iclaprim versus intravenous vancomycin in the treatment of ABSSSI. The iclaprim fixed dose regime can help reduce the time required for dosage adjustment or monitoring by healthcare professionals in renally impaired or obese patients, leading to reduced overall hospital treatment costs in these high risk patient populations. Studies have found that hospitalized patients with ABSSSI have a higher occurrence of obesity and renal impairment than in the general adult population. Obesity can affect the pharmacokinetics and pharmacodynamics of many drugs, including antimicrobial therapies, potentially leading to suboptimal drug concentrations in serum or tissue. Obese patients have been found to be at risk for clinical failure following inadequate dosing of antimicrobial therapy.

Dr. David Huang, Chief Medical Officer at Motif, said: "Concurrence from the FDA of the potential efficacy and safety benefits of this fixed dose regime is important for the iclaprim Phase III trials and, assuming approval, will offer clear benefits for practitioners and patients. The fixed dose regime should save significant time treating high risk patients where a rapid response is critical."

For further information please contact

Enquiries:

Notes to Editors:

Motif is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria. For additional information about Motif please visit www.motifbio.com.